作者
Rita E Chen, Xianwen Zhang, James Brett Case, Emma S Winkler, Yang Liu, Laura A VanBlargan, Jianying Liu, John M Errico, Xuping Xie, Naveenchandra Suryadevara, Pavlo Gilchuk, Seth J Zost, Stephen Tahan, Lindsay Droit, Jackson S Turner, Wooseob Kim, Aaron J Schmitz, Mahima Thapa, David Wang, Adrianus CM Boon, Rachel M Presti, Jane A O’Halloran, Alfred HJ Kim, Parakkal Deepak, Dora Pinto, Daved H Fremont, James E Crowe Jr, Davide Corti, Herbert W Virgin, Ali H Ellebedy, Pei-Yong Shi, Michael S Diamond
发表日期
2021/4
期刊
Nature medicine
卷号
27
期号
4
页码范围
717-726
出版商
Nature Publishing Group US
简介
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor-binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike receptor-binding domain and N …
学术搜索中的文章
RE Chen, X Zhang, JB Case, ES Winkler, Y Liu… - Nature medicine, 2021
M Diamond, R Chen, X Xie, J Case, X Zhang… - Research square, 2021